Evidence map›Paper›PMID 38516553›Full record

ArticleMuscles (Basel, Switzerland)2023

Pathological Sequelae Associated with Skeletal Muscle Atrophy and Histopathology in G93A*SOD1 Mice.

Richa Aishwarya, Chowdhury S Abdullah, Naznin Sultana Remex, Sadia Nitu, Brandon Hartman, Judy King, Mohammad Alfrad Nobel Bhuiyan, Oren Rom, Sumitra Miriyala, Manikandan Panchatcharam and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Muscles (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Targets and Gene Therapy of ALS (Part 1).International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Richa AishwaryaDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Chowdhury S AbdullahDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Naznin Sultana RemexDepartment of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Sadia NituDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Brandon HartmanDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Judy KingDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Mohammad Alfrad Nobel BhuiyanDepartment of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0002-6011-2624
Oren RomDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0002-9272-086X
Sumitra MiriyalaDepartment of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Manikandan PanchatcharamDepartment of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0002-7691-8948
A Wayne OrrDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Christopher G KevilDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Md Shenuarin BhuiyanDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0003-0073-3071
Louisiana State University Health Sciences Center Shreveport · US

Funding

Stress Exacerbates Myocardial Ischemic Injury by Blocking Estrogen's Antidoxidant Protection in the Female HeartP20GM121307 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Mohammad Alfrad Nobel Bhuiyan · 2018 to 2026
$23.6M
Nck Adaptor Proteins in Atherogenic Endothelial ActivationR01HL133497 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2016 to 2024
$3.8M
Matrix Signaling in Endothelial Cell DysfunctionR01HL098435 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2010 to 2020
$3.2M
Fortilin, CTNNA3, and the HeartR01HL152723 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN · 2021 to 2024
$2.7M
Sigmar1 in lipid metabolismR01HL145753 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BHUIYAN, MD. SHENUARIN · 2019 to 2023
$2.6M
Lipidated Amino Acids in Cardiometabolic DiseasesR01DK134011 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2022 to 2026
$2.1M
EphA2 signaling in atherosclerotic fibroproliferative remodelingR01HL141155 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2019 to 2022
$1.8M
CSE regulation of vascular remodelingR01HL149264 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI KEVIL, CHRISTOPHER G · 2020 to 2023
$1.7M
Mechanisms of glycine-based therapy for atherosclerosisR00HL150233 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ROM, OREN SHALOM · 2021 to 2023
$747k
Sigma-1 receptor and cardioprotectionR00HL122354 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BHUIYAN, MD. SHENUARIN · 2015 to 2017
$747k
Prenatal ethanol mediated regulation of bioactive lipid: Role of Autotaxin and LPP3 in Alzheimer disease.R15HL141998 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI MIRIYALA, SUMITRA · 2018 to 2019
$508k
Alcohol-LPP3 axis in ischemic strokeR21AA025744 · NIAAA · LOUISIANA STATE UNIV HSC SHREVEPORT · PI PANCHATCHARAM, MANIKANDAN · 2017 to 2018
$483k
American Heart Association-American Stroke Association 20POST35210789 - CHOWDHURY ABDULLAHNHLBI NIH HHS K99 HL122354NHLBI NIH HHS K99 HL150233NHLBI NIH HHS R00 HL122354NHLBI NIH HHS R00 HL150233NHLBI NIH HHS R01 HL098435NHLBI NIH HHS R01 HL133497NHLBI NIH HHS R01 HL141155NHLBI NIH HHS R01 HL145753NHLBI NIH HHS R01 HL149264NHLBI NIH HHS R01 HL152723NHLBI NIH HHS R15 HL141998NIAAA NIH HHS R21 AA025744NIAAA NIH HHS R21 AA026708NIDDK NIH HHS R01 DK134011NIGMS NIH HHS P20 GM121307
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a complex systemic disease that primarily involves motor neuron dysfunction and skeletal muscle atrophy. One commonly used mouse model to study ALS was generated by transgenic expression of a mutant form of human superoxide dismutase 1 (SOD1) gene harboring a single amino acid substitution of glycine to alanine at codon 93 (G93A*SOD1). Although mutant-SOD1 is ubiquitously expressed in G93A*SOD1 mice, a detailed analysis of the skeletal muscle expression pattern of the mutant protein and the resultant muscle pathology were never performed. Using different skeletal muscles isolated from G93A*SOD1 mice, we extensively characterized the pathological sequelae of histological, molecular, ultrastructural, and biochemical alterations. Muscle atrophy in G93A*SOD1 mice was associated with increased and differential expression of mutant-SOD1 across myofibers and increased MuRF1 protein level. In addition, high collagen deposition and myopathic changes sections accompanied the reduced muscle strength in the G93A*SOD1 mice. Furthermore, all the muscles in G93A*SOD1 mice showed altered protein levels associated with different signaling pathways, including inflammation, mitochondrial membrane transport, mitochondrial lipid uptake, and antioxidant enzymes. In addition, the mutant-SOD1 protein was found in the mitochondrial fraction in the muscles from G93A*SOD1 mice, which was accompanied by vacuolized and abnormal mitochondria, altered OXPHOS and PDH complex protein levels, and defects in mitochondrial respiration. Overall, we reported the pathological sequelae observed in the skeletal muscles of G93A*SOD1 mice resulting from the whole-body mutant-SOD1 protein expression.

Indexed as

ALSG93A*SOD1histopathologymitochondriaskeletal muscle

Identifiers

PMID38516553
PMCPMC10956373
OpenAlexW4319080765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.